ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 1865

Identification of Parameters Associated with a Diagnostic Delay in Axial Spondyloarthritis:Results from the European Map of Axial Spondyloarthritis (EMAS)

Marco Garrido-Cumbrera1, Victoria Navarro-Compán2, Christine Bundy3, Raj Mahapatra4, Souzi Makri5, José Correa-Fernández6, Laura Christen7, Carlos-Jesus Delgado-Domínguez8 and Denis Poddubnyy9, 1Health & Territory Research (HTR), Universidad de Sevilla / Spanish Federation of Spondyloarthritis Associations, Sevilla, Spain, 2Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, 3Cardiff University, Cardiff, United Kingdom, 4Axial Spondyloarthritis International Federation, London, United Kingdom, 5Cyprus League Against Rheumatism, Nicosia, Cyprus, 6Health & Territory Research (HTR), Universidad de Sevilla, Sevilla, Spain, 7Novartis Pharma AG, Basel, Switzerland, 8Health & Territory Research, Seville, Spain, 9Charité – Universitätsmedizin Berlin, Berlin, Germany

Meeting: ACR Convergence 2020

Keywords: spondyloarthritis

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Early diagnosis of Axial Spondyloarthritis (axSpA) is crucial for timely access to specialist care and effective treatment. The aim is to assess the current diagnostic delay in axSpA and identify the parameters associated with increased diagnostic delay in a European sample.

Methods: Data from unselected patients participating in the European Map of Axial Spondyloarthritis (EMAS) study through an online survey (2017- 2018) across 13 countries were analysed. Mean differences in diagnostic delay were analysed using Mann-Whitney and Kruskal-Wallis tests, among sociodemographic and disease-related factors. A multivariate linear regression analysis was carried out to identify the relative weight of the associated parameters in determining diagnostic delay.

Results: 2,846 patients participated in EMAS. Mean age was 43.9 years, 61.3% were female, 48.1% had a university degree, and 53.9% were employed. Of the 2846 participants, 2652 provided information for calculating diagnostic delay. Mean age at symptom onset was 26.6 ± 11.1, mean age at diagnosis was 33.7 ± 11.5, and mean diagnostic delay was 7.4 ± 8.4 (Fig. 1). The following variables were associated with longer diagnostic delay in the bivariate analysis: older age, female gender, being diagnosed by a rheumatologist (Table 1). In the multivariate regression analysis younger age at symptom onset, number of HCPs seen before were associated with diagnostic delay (Table 2).

Conclusion: In this large sample of axSpA patients from 13 different European countries, the average diagnostic delay was more than seven years. The fact that one of the most strongly associated parameters to diagnostic delay was number of HCPs seen before diagnosis suggests the need for urgent action to reduce incorrect referrals to shorten the patient journey to diagnosis across Europe.

Figure 1. Average years of diagnostic delay across EMAS countries (N: 2,652)

Table 1. Associations between sociodemographic and disease-related variables and diagnostic delay (N: 2,652)


Disclosure: M. Garrido-Cumbrera, None; V. Navarro-Compán, Novartis Pharma, 1, 5, 8, AbbVie Inc., 5, 8, Eli Lilly and Company, 5, 8, Pfizer Inc., 5, UCB, 5, 8; C. Bundy, Abbvie, 8, Celgene, 8, Janssen, 8, Lilly, 8, Novartis, 8, Pfizer, 8; R. Mahapatra, None; S. Makri, None; J. Correa-Fernández, None; L. Christen, Novartis Pharma AG, 3; C. Delgado-Domínguez, None; D. Poddubnyy, Eli Lilly and Company, 2, 5, 8, MSD, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, BioCad, 5, Gilead, 5, GSK, 5, UCB, 5, 8, BMS, 8.

To cite this abstract in AMA style:

Garrido-Cumbrera M, Navarro-Compán V, Bundy C, Mahapatra R, Makri S, Correa-Fernández J, Christen L, Delgado-Domínguez C, Poddubnyy D. Identification of Parameters Associated with a Diagnostic Delay in Axial Spondyloarthritis:Results from the European Map of Axial Spondyloarthritis (EMAS) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/identification-of-parameters-associated-with-a-diagnostic-delay-in-axial-spondyloarthritisresults-from-the-european-map-of-axial-spondyloarthritis-emas/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-parameters-associated-with-a-diagnostic-delay-in-axial-spondyloarthritisresults-from-the-european-map-of-axial-spondyloarthritis-emas/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology